Literature DB >> 18334131

Treatment options for Duchenne muscular dystrophy.

Emma Ciafaloni1, Richard T Moxley.   

Abstract

The main goal in the treatment of Duchenne muscular dystrophy (DMD) is to maintain ambulation for as long as possible and to anticipate and manage the associated complications, such as joint contractures, scoliosis, cardiomyopathy, respiratory insufficiency, and weight gain. Cognitive and behavioral symptoms occur in about one third of patients, and it is important to recognize and manage them promptly, developing an individualized plan at school and at home to maximize the patient's cognitive abilities. In the late phase of the disease, palliative care is of paramount importance. Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD. Daily prednisone treatment increases muscle strength and function, improves pulmonary function, and significantly slows the progression of weakness. Deflazacort has a similar effect on muscle strength, but it is not available in the United States. Treatment with corticosteroid should be offered to all patients with DMD, but the beneficial effects and potential adverse effects should be fully discussed before treatment begins. The optimal dose of prednisone is 0.75 mg/kg per day, up to a maximum of 40 mg/d. If adverse effects occur, a decrease in dosage is appropriate. Monitoring of muscle function and adverse effects by a neurologist or neuromuscular specialist is strongly recommended. Physical and occupational therapists should be involved early in the treatment of patients with DMD to develop a program that includes heel cord stretching and exercise. In the later phases, these therapists can recommend adaptive equipment and maximize independence. Orthopedic consultation is important in monitoring and managing scoliosis and joint contractures in the nonambulatory phase of the disease. Pulmonary evaluation for ventilatory care is important; pulmonary consultation is essential when vital capacity declines. The use of assistive cough devices, nasal bilevel positive airway pressure, and tracheostomy must be discussed with patients and their families. For all patients with DMD, particularly those receiving prednisone, consultation with a dietitian is very helpful to control weight and maintain a healthy diet.

Entities:  

Year:  2008        PMID: 18334131     DOI: 10.1007/s11940-008-0010-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  19 in total

1.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

2.  Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.

Authors:  Samit Hirawat; Ellen M Welch; Gary L Elfring; Valerie J Northcutt; Sergey Paushkin; Seongwoo Hwang; Eileen M Leonard; Neil G Almstead; William Ju; Stuart W Peltz; Langdon L Miller
Journal:  J Clin Pharmacol       Date:  2007-04       Impact factor: 3.126

Review 3.  The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature.

Authors:  J P Bakker; I J de Groot; H Beckerman; B A de Jong; G J Lankhorst
Journal:  Clin Rehabil       Date:  2000-08       Impact factor: 3.477

4.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

5.  Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up.

Authors:  Denis Duboc; Christophe Meune; Bertrand Pierre; Karim Wahbi; Bruno Eymard; Annick Toutain; Carole Berard; Guy Vaksmann; Simon Weber; Henri-Marc Bécane
Journal:  Am Heart J       Date:  2007-09       Impact factor: 4.749

6.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  W M King; R Ruttencutter; H N Nagaraja; V Matkovic; J Landoll; C Hoyle; J R Mendell; J T Kissel
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

7.  American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation.

Authors:  David J Birnkrant; Howard B Panitch; Joshua O Benditt; Louis J Boitano; Edward R Carter; Valerie A Cwik; Jonathan D Finder; Susan T Iannaccone; Lawrence E Jacobson; Gary L Kohn; Etsuro K Motoyama; Richard T Moxley; Mary K Schroth; Girish D Sharma; Michael D Sussman
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

8.  Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.

Authors:  Kathryn R Wagner; Alexandra C McPherron; Nicole Winik; Se-Jin Lee
Journal:  Ann Neurol       Date:  2002-12       Impact factor: 10.422

Review 9.  Gene therapy for duchenne muscular dystrophy: expectations and challenges.

Authors:  Louise R Rodino-Klapac; Louis G Chicoine; Brian K Kaspar; Jerry R Mendell
Journal:  Arch Neurol       Date:  2007-09

10.  Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs.

Authors:  Maurilio Sampaolesi; Stephane Blot; Giuseppe D'Antona; Nicolas Granger; Rossana Tonlorenzi; Anna Innocenzi; Paolo Mognol; Jean-Lauren Thibaud; Beatriz G Galvez; Ines Barthélémy; Laura Perani; Sara Mantero; Maria Guttinger; Orietta Pansarasa; Chiara Rinaldi; M Gabriella Cusella De Angelis; Yvan Torrente; Claudio Bordignon; Roberto Bottinelli; Giulio Cossu
Journal:  Nature       Date:  2006-11-15       Impact factor: 49.962

View more
  9 in total

1.  Myogenin regulates exercise capacity but is dispensable for skeletal muscle regeneration in adult mdx mice.

Authors:  Eric Meadows; Jesse M Flynn; William H Klein
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

2.  Perceived effectiveness and barriers to physical therapy services for families and children with Friedreich ataxia.

Authors:  Joyce Maring; Earllaine Croarkin; Sylvia Morgan; Margaret Plack
Journal:  Pediatr Phys Ther       Date:  2013       Impact factor: 3.049

3.  Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts.

Authors:  Herman Vandenburgh; Janet Shansky; Frank Benesch-Lee; Kirsten Skelly; Janelle M Spinazzola; Yero Saponjian; Brian S Tseng
Journal:  FASEB J       Date:  2009-06-01       Impact factor: 5.191

4.  Evaluation of Early Left Ventricular Dysfunction in Patients with Duchenne Muscular Dystrophy Using Two-Dimensional Speckle Tracking Echocardiography and Tissue Doppler Imaging.

Authors:  Min-Jung Cho; Ji-Won Lee; JeSang Lee; Yong Beom Shin
Journal:  Pediatr Cardiol       Date:  2018-07-12       Impact factor: 1.655

5.  Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy.

Authors:  Forod Salehi; Aliakbar Zeinaloo; Hamid Reza Riasi; Alireza Sepehri Shamloo
Journal:  Electron Physician       Date:  2017-03-25

6.  Feasibility and tolerability of whole-body, low-intensity vibration and its effects on muscle function and bone in patients with dystrophinopathies: a pilot study.

Authors:  Anna Petryk; Lynda E Polgreen; Molly Grames; Dawn A Lowe; James S Hodges; Peter Karachunski
Journal:  Muscle Nerve       Date:  2017-02-06       Impact factor: 3.217

Review 7.  CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.

Authors:  Guofang Chen; Tingyi Wei; Hui Yang; Guoling Li; Haisen Li
Journal:  Cells       Date:  2022-09-22       Impact factor: 7.666

8.  Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?

Authors:  Cathleen Buckon; Susan Sienko; Anita Bagley; Mitell Sison-Williamson; Eileen Fowler; Loretta Staudt; Kent Heberer; Craig M McDonald; Michael Sussman
Journal:  PLoS Curr       Date:  2016-07-08

Review 9.  A Spotlight on T Lymphocytes in Duchenne Muscular Dystrophy-Not Just a Muscle Defect.

Authors:  Chantal A Coles; Ian Woodcock; Daniel G Pellicci; Peter J Houweling
Journal:  Biomedicines       Date:  2022-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.